熱門詞： 進口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進口電動高溫調(diào)節(jié)閥-德國進口電動高溫法蘭調(diào)節(jié)閥進口電動蒸汽調(diào)節(jié)閥-德國進口電動蒸汽調(diào)節(jié)閥
熱門詞： 進口電動溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進口電動溫度調(diào)節(jié)閥數(shù)據(jù)表進口電動高溫調(diào)節(jié)閥-德國進口電動高溫法蘭調(diào)節(jié)閥進口電動蒸汽調(diào)節(jié)閥-德國進口電動蒸汽調(diào)節(jié)閥
BIND Therapeutics 美國BIND Therapeutics
BIND的生物科技是一家生物制藥公司，開發(fā)治療深刻改善集中在靶組織的藥物，同時盡量減少系統(tǒng)性風險患者的生活能有針對性的納米粒子。我們的技術(shù)平臺，提供了獨特的能力，為他們的特定應(yīng)用優(yōu)化治療精確，重復(fù)性納米我們。
BIND公司制藥科學(xué)副總裁杰夫·哈凱基表示，這是首個進入臨床實踐的可遞送化療藥物的靶向型納米粒子。接下來，公司會將其發(fā)展成一個平臺，用于治療心血管疾病、各類炎癥，甚至傳染性疾病。
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.
知識產(chǎn)權(quán)侵權(quán)投訴：不生產(chǎn)任何產(chǎn)品所有產(chǎn)品均來自產(chǎn)品的生產(chǎn)廠商、代理商、經(jīng)銷商，如有侵權(quán)請聯(lián)系：400-006-7520 ，我們會在第一時間處理
本網(wǎng)站所有產(chǎn)品與藥品無關(guān)
滬公網(wǎng)安備31011502016460號
